FDA approves Eliquis® (apixaban) to reduce the risk of blood clots following hip or knee replacement surgery

Source: Medical News Today

Bristol-Myers Squibb Company and Pfizer Inc. has announced that the U.S. Food and Drug Administration (FDA) approved a Supplemental New Drug Application (sNDA) for Eliquis (apixaban) for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery.

Read More